Kinrix Vaccine Description 2024
Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) is a noninfectious, sterile vaccine for intramuscular administration. Kinrix includes D-antigen Units (DU) of Type 1 poliovirus (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett).
The inactivated poliovirus component of Kinrix is an enhanced potency component. Each of the three poliovirus strains is individually grown in VERO cells, a continuous line of monkey kidney cells cultivated on microcarriers. The three purified viral strains are pooled to form a trivalent concentrate. The diphtheria, tetanus, and pertussis components of KINRIX are the same as those in INFANRIX and PEDIARIX, and the poliovirus component is the same as that in PEDIARIX.
GlaxoSmithKline Biologicals - U.S. FDA approved 2008 (STN: BL 125260; BL 125260/703)
Kinrix Vaccine Indication
A single dose of Kinrix is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.
Kinrix Dosage
Kinrix is administered as a single intramuscular injection. The preferred site of administration is the deltoid muscle of the upper arm.
Kinrix News
October 27, 2023 - We have approved your request received on April 28, 2023, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (KINRIX), manufactured at your facilities in Rixensart Belgium.
August 1, 2022 - Global Polio Laboratory Network (GPLN) confirmed that the case in New York is genetically linked to two Sabin-like type 2 (SL2) isolates collected from the early June samples from Rockland County and samples from greater Jerusalem, Israel, as well as to the recently-detected VDPV2 from environmental samples in London, UK.
March 31, 2021 - Combination Vaccine Market May See a Big Move.
August 5, 2020 - DTAP VACCINE MARKET IS ESTIMATED TO GROW AT THE HIGHEST GROWTH RATE TILL 2027 | GLAXOSMITHKLINE, SANOFI PASTEUR, PROTEIN SCIENCES CORPORATION, NOVARTIS AG
Kinrix Clinical Trials
GSK's Kinrix has tested immunogenicity, safety, and duration of protection in various clinical trials.
